Erasca: Strong Data Overshadowed By A Patient Death And A Patent Fight
Erasca is a high-risk, high-reward clinical-stage biotech focused on RAS/MAPK pathway-driven cancers. Click here to read this latest analysis of ERAS stock.
Opening excerpt (first ~120 words) tap to expand
{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://seekingalpha.com/"},{"@type":"ListItem","position":2,"name":"Healthcare ","item":"https://seekingalpha.com/stock-ideas/healthcare"}]}{"@context":"https://schema.org","@type":"NewsArticle","mainEntityOfPage":{"@type":"WebPage","@id":"https://seekingalpha.com/article/4895339-erasca-strong-data-overshadowed-by-a-patient-death-and-a-patent-fight"},"author":{"@type":"Person","name":"Stephen Ayers","url":"https://seekingalpha.com/author/stephen-ayers"},"publisher":{"@context":"http://schema.org","@type":"Organization","address":{"@type":"PostalAddress","streetAddress":"244 5th Ave","addressLocality":"New…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Seeking Alpha.
Discussion
0 commentsMore from Seeking Alpha
